+Compare
RETA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
6.57B

RETA Price Prediction, Reata Pharmaceuticals AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for RETA with price predictions
08:00 PM EDT Sep 24, 2023

Momentum Indicator for RETA turns positive, indicating new upward trend

RETA saw its Momentum Indicator move above the 0 level on August 31, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RETA advanced for three days, in of 267 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 229 cases where RETA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RETA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RETA broke above its upper Bollinger Band on September 07, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RETA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (75.188) is normal, around the industry mean (22.620). P/E Ratio (0.000) is within average values for comparable stocks, (131.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.087). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (285.714) is also within normal values, averaging (306.625).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I. Advisor
published Earnings

RETA is expected to report earnings to fall 13.36% to -214 cents per share on November 07

Reata Pharmaceuticals RETA Stock Earnings Reports
Q3'23
Est.
$-2.14
Q2'23
Missed
by $2.12
Q1'23
Beat
by $0.60
Q4'22
Missed
by $0.02
Q3'22
Beat
by $0.74
The last earnings report on August 07 showed earnings per share of -247 cents, missing the estimate of -34 cents. With 1.98M shares outstanding, the current market capitalization sits at 6.57B.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.17B. The market cap for tickers in the group ranges from 402 to 407B. NVO holds the highest valuation in this group at 407B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was 16%, and the average quarterly price growth was 36%. SLNO experienced the highest price growth at 494%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 72%. For the same stocks of the Industry, the average monthly volume growth was 150% and the average quarterly volume growth was 108%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of pharmaceutical products for treatment of inflammatory diseases and cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
5320 Legacy Drive
Phone
+1 972 865-2219
Employees
323
Web
https://www.reatapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BIV72.43-0.06
-0.08%
Vanguard Interm-Term Bond ETF
GRPM85.58-0.99
-1.15%
Invesco S&P MidCap 400® GARP ETF
ISZE24.53-0.32
-1.29%
iShares MSCI Intl Size Factor ETF
EIM9.05-0.13
-1.42%
Eaton Vance Municipal
NETL21.52-0.63
-2.84%
Fundamental Income Net Lease Rl Estt ETF

RETA and

Correlation & Price change

A.I.dvisor indicates that over the last year, RETA has been loosely correlated with SRPT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if RETA jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RETA
1D Price
Change %
RETA100%
N/A
SRPT - RETA
44%
Loosely correlated
+4.07%
NTLA - RETA
41%
Loosely correlated
+0.43%
MDGL - RETA
39%
Loosely correlated
-1.32%
TSVT - RETA
36%
Loosely correlated
+6.81%
AVIR - RETA
36%
Loosely correlated
-3.49%
More